Moderna (MRNA) Gross Margin (2020 - 2026)

Moderna (MRNA) has 7 years of Gross Margin data on file, last reported at 145.5% in Q1 2026.

• Gross Margin for Q1 2026 came in at 145.5%, down 16217.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.11% (down 3104.0% YoY), and the FY2025 annual result was 55.35%, up 59.0% from the prior year.
• Gross Margin declined to 145.5% in Q1 2026 per MRNA's latest filing, from 33.33% in the prior quarter.
• Over five years, Gross Margin peaked at 92.13% in Q4 2022 and troughed at 145.5% in Q1 2026.
• A 5-year average of 28.03% and a median of 42.51% in 2024 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2023 and 2024: Gross Margin plunged 18342 bps in 2023, then surged 14716 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 92.13% in 2022, then declined by 27 bps to 66.95% in 2023, then slumped by 65 bps to 23.5% in 2024, then jumped by 42 bps to 33.33% in 2025, then sank by 537 bps to 145.5% in 2026.
• Business Quant data shows MRNA's Gross Margin at 145.5% in Q1 2026, 33.33% in Q4 2025, and 79.63% in Q3 2025.